The group's principal activities are to research, develop and distribute new anti-infective drugs to combat life-threatening bacterial and fungal infections. The main product being cidecin, which is used for the treatment of complicated skin and skin structure infections. The group has two additional drug candidates in pre-clinical trials. One of them is an intravenous cephalosporin, cab-175 and the other, an oral formulation of ceftriaxone. It is also focused on the identification of novel compounds with a broad spectrum of activity against a variety of infections using natural product and other technologies. Majority of the revenues is generated within the United States.
